Shareholder Class Action

Directors of Sequenom inflated share price with false and misleading statements about its genetic diagnostic test, SEQureDx, shareholders claim in San Diego Federal Court.           Shareholders challenge HLTH Corp.’s $1.2 billion merger with WebMD Health Corp., in New York County Court.           Shareholders say directors of FiberNet Telecom Group are selling the company too cheaply to the Zayo Group – for $11.45 a share, or $88 million – though RCN Corp. offered $12.50 a share, in Delaware Chancery Court.           Shareholders claims CuraGen is selling itself too cheaply to Celldex Therapeutics, for $94.5 million, o4 $1.55 a share, in New Haven Superior Court.